In our new video our MD, Seema Sharma, talks about our specialist scientific marketing agency. We focus on our services, team and the sectors we cover. In addition, we include some recent global examples of life science marketing projects. For example research instrumentation campaign launches, digital marketing for life science reagents, and SEO for scientific publishing.
We are a full service scientific marketing agency
If you are looking for marketing strategy, brand & design, digital marketing, copywriting, or PR in a scientific field, please contact the team. We’d be happy to provide advice and let you know more about what we do: email@example.com
AZD1222, a COVID-19 vaccine that has just undergone phase 3 trials, was co-developed by the spin-out company, Vaccitech, based at the University of Oxford and AstraZeneca. It uses a replication-deficient chimpanzee viral vector based on an attenuated (weakened) version of a common cold adenovirus. The latter has been modified to include the DNA sequence of the SARS-CoV-2 virus spike protein. As a result, this surface spike protein is produced in the recipients body post-vaccination. It is the most antigenic part of COVID-19, eliciting an antibody response, and priming the immune system to counteract future infections.
Overview of COVID-19 Vaccine Trial (Phase 3) Results:
Vaccine Name: AZD1222
Developers: Astra Zeneca + VacciTech (Oxford University) UK
Vaccine details: Chimpanzee Adenovirus vector (attenuated) + Sars-Cov2 spike protein DNA
Approach: Two dosing regimens (inadvertent – see below for explanation)
statistical significance: p-value <=0.0001
Dose – Day 1
Dose – Day 28
Number of test subjects
Figures released to the press  included a composite average efficacy of 70%. In reality there were effectively two trials, due to the difference in doses. The half dose was actually given in error initially, to 2.7K+ test volunteers. This subgroup who received an erroneous administration, actually produced the most pronounced efficacy (90%). Speculative theories around this suggest, the lower dose may stimulate T cell production of antibodies more effectively. Alternatively, the patients who received the higher dose on day 1 may have experienced a more pronounced reaction to components of the viral vector itself. Thus, the response to the second dose was blunted (62%).
Clearly, more research is needed to establish the cause. Additional data on the age and ethnicity breakdown of the individuals included in the higher efficacy subgroup would also be necessary to ensure the trial group was representative of the population at large and no biases were present. For example, an absence of individuals who were 65+, or from ethnic minority groups in the higher efficacy group, has a potential to skew results.
The researchers stated no severe cases of COVID-19 or hospitalisations were recorded in any patients, where the vaccine proved ineffective.
Note that whilst phase 1/2 trials of the vaccine have been published with peer-review , we still await the full results and data of the phase 3 trial.
The Oxford University and AstraZeneca team have also made a commitment to broad and equitable global access to the vaccine. https://www.ox.ac.uk/news/2020-06-05-oxford-university-s-covid-19-vaccine-next-steps-towards-broad-and-equitable-global
Pros & Cons of Adenovirus Vaccines Vs RNA vaccines
Established and large scale production techniques available
Thermostable, at normal cold storage temperatures 2-8oC
Prospect of annual boosters required
Update 30th December 2020:
The UK Medicines and Healthcare products Regulatory Agency (MHRA) authorised the emergency supply of COVID-19 Vaccine (AZD1222) for the immunisation of individuals 18 years+. This authorisation recommended the two full dose regimens be given – due to a lack of data for the half dose/ full dose regimen at present. They have recommended that the two identical doses be given with a 4 to 12 week interval.
Publisher: About Us – Onyva The Agency
We are a scientific marketing agency. We have continued to support clients through the current pandemic, producing technical literature, articles and digital marketing support relating specifically to COVID-19 for the medical, healthcare and biotechnology industries. Our scientifically trained team are able to combine up-to-date knowledge on the evolving pandemic, with decades of marketing experience to meet you needs.Take a look at our services.
Get in touch for marketing support: firstname.lastname@example.org
1. AstraZeneca Press Release: 23 Nov 2020 https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr
2. Folegatti PM, Ewer Kj et al., Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20. Erratum in: Lancet. 2020 Aug 15;396(10249):466. PMID: 32702298; PMCID: PMC7445431.
We’re celebrating 5 years since our launch this month! Onyva the Agency, founded by our MD Seema Sharma, officially launched in September 2015. We have been providing marketing services to the scientific sector for half a decade! During that time we’ve partnered with diverse clients in scientific publishing, biotechnology, medical diagnostics, research instrumentation and cancer charity sectors, to name a few.
‘We’re very proud to have reached this milestone, and provide our marketing expertise combined with our scientific and industry-specific knowledge to our growing client base. The recent challenges faced globally with the Covid-19 pandemic, have meant that we’ve had to work more closely to support the health, medical and life sciences sector in rapidly emerging situations with tight deadlines. We’re looking forward to the next 5 years, and expanding our Public Relations and bespoke marketing software offering.’
Dr. Seema Sharma. Founder and MD, Onyva the Agency.
SEO is an iterative process. As such, you need to keep abreast of multiple ranking factors, and their potential weighting in proprietary search engine algorithm updates to make changes that matter. Our infographic provides a straight-forward SEO checklist into tactics and resources, to ensure you’ve got the key things covered.
SEO in the B2B scientific sector
Navigating SEO in a B2B setting for product marketing in the life sciences, biotech, medical or tech fields is business critical. Although, it comes with it’s own unique challenges, versus B2C or retail sectors. You’ll likely be including very similar technical terminology to your competitors, therefore, will need to experiment and use innovative ways to ensure you rank ahead.
Key steps in your SEO plan
If you are at the early stages of formulating an SEO plan, here are some key questions to ask:
What are your goals for SEO, and how much budget do you have to assign to it?
What are customers searching for, to find your product or services?
If the answer here is “we are not sure,” or “we are subjectively guessing what it is,”, you will need to dedicate time for search term and keyword research. When you’re marketing B2B, as a life sciences, biotechnology, medical or tech company, you’ll undoubtedly have considerable in-house expertise. As a result, it can be tempting to second guess and assume you know how a customer will behave.Whilst your specialist knowledge can serve you well, we’ve encountered many instances where clients have been surprised to learn how their users are finding their products. Remember, subtle differences and variations in keywords can have a profound impact on SEO. Furthermore, keyword research tools (e.g Google Keyword Planner , Moz’s Keyword explorer and SEM Rush, to name a few, can be a huge help. Tie these in with information from search term reports from PPC, Google Trends , or other similar tools and you have a great start. One issue you may face in a B2B environment with specialised products, is a lack of search volume for definitive data. One approach here would be to supplement data with direct user interactions from surveys.
Some key questions and points to consider when optimising your SEO strategy and content:
Based on your research what keywords do you want to rank highly for?
What are competitors ranking highly for?
Are you ensuring you use your SEO research to drive your online content marketing and distribution plan? (NB: it should be this way around).
Will your content help you earn inbound links? Take a look at whose linking to your competitors – would they link to your content as well?
Do you have a social media plan to share content, and drive users back to your site?
How are you going to measure success? What metrics are key?
Have you got your on-page SEO optimised? Meta-descriptions are critical as Google matches searches based on this content and displays them in SERPS. Also consider, the slug, keyword density, and readability factors (sub-heading distribution, paragraph structure, use of active voice and transition words etc.,)
Still need more help with implementing website SEO? We offer a comprehensive service to help improve search rankings,combined with technical content production. Get in touch with our team now.